# Effectiveness and selection of exercise prescriptions for myocardial infarction patients: a systematic review and meta-analysis

**Authors:** Shiguang Ren, Yinping Zeng, Kun Qin, Yunzhu Hua, Jae Cheol Kim, Wenduo Liu, Zilin Wang

PMC · DOI: 10.3389/fcvm.2026.1739046 · Frontiers in Cardiovascular Medicine · 2026-02-23

## TL;DR

This study reviews how exercise helps heart attack patients recover, finding that moderate exercise improves heart function and quality of life, but more high-quality research is needed.

## Contribution

The study provides evidence-based guidance on optimal exercise prescriptions for myocardial infarction rehabilitation.

## Key findings

- Exercise improves cardiac function, exercise performance, and quality of life in MI patients.
- Moderate-intensity aerobic or resistance training for >16 weeks is most beneficial for MI rehabilitation.
- Current evidence on resistance training is limited and subject to bias.

## Abstract

Exercise intervention has garnered significant attention for its potential to promote recovery and improve outcomes in myocardial infarction (MI) patients. However, controversy persists regarding the efficacy of exercise prescriptions in related studies. Therefore, this research aims to analyze the effects of exercise prescriptions during MI rehabilitation and associated influencing factors through systematic review and meta-analysis, thereby providing guidance for exercise prescription selection in MI patients.

A systematic review and meta-analysis were conducted by retrieving data from PubMed, Web of Science, and Scopus databases between January 2015 and June 2025. Only meta-analyses using random-effects models for cardiac function were included in the study. Subgroup analyses were conducted based on exercise type, intensity, session duration, frequency, and intervention duration.

A total of 42 studies were included. The results showed that exercise intervention significantly improves cardiac function, exercise performance, and quality of life in MI patients, while significantly reducing the incidence of adverse cardiovascular events. A subgroup analysis of 26 cardiac function studies revealed that variations in exercise type, intensity, frequency, session duration, and intervention duration all exerted modulatory effects on left ventricular ejection fraction (LVEF) levels in MI patients. However, the certainty of evidence related to LVEF is generally low, and the pooled effect is mainly influenced by non-randomized studies with high risk of bias. Furthermore, the evidence is subject to inconsistency and/or imprecision, leading to a potential low or very low certainty in conclusions.

Current findings indicate that moderate-intensity aerobic or resistance training, with each session lasting < 30 min, < 3 times per week, and an intervention duration > 16 weeks, is more beneficial for the rehabilitation of MI patients. The clinical research on resistance training is currently insufficient, and some studies have a high risk of bias. Additionally, there is considerable heterogeneity in the heart function intervention methods (e.g., type, session duration, frequency, intensity, and intervention duration), which could potentially influence the research outcomes. Therefore, more high-quality studies are needed in the future to validate these findings and provide more reliable scientific evidence for optimizing rehabilitation strategies for MI patients.

https://www.crd.york.ac.uk/PROSPERO/view/CRD420251085069, PROSPERO CRD420251085069.

## Linked entities

- **Diseases:** myocardial infarction (MONDO:0005068)

## Full-text entities

- **Genes:** SIRT1 (sirtuin 1) [NCBI Gene 23411] {aka SIR2, SIR2L1, SIR2alpha}, SOD2 (superoxide dismutase 2) [NCBI Gene 6648] {aka GC1, GClnc1, IPO-B, IPOB, MNSOD, MVCD6}, PPARGC1A (PPARG coactivator 1 alpha) [NCBI Gene 10891] {aka LEM6, PGC-1(alpha), PGC-1alpha, PGC-1v, PGC1, PGC1A}, PRKAB1 (protein kinase AMP-activated non-catalytic subunit beta 1) [NCBI Gene 5564] {aka AMPK, HAMPKb}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, DUOX2 (dual oxidase 2) [NCBI Gene 50506] {aka LNOX2, NOXEF2, P138-TOX, TDH6, THOX2}, NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, CAT (catalase) [NCBI Gene 847], IL1RN (interleukin 1 receptor antagonist) [NCBI Gene 3557] {aka CRMO2, DIRA, ICIL-1RA, IL-1RN, IL-1ra, IL-1ra3}, AGT (angiotensinogen) [NCBI Gene 183] {aka ANHU, SERPINA8, hFLT1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}
- **Diseases:** RE (MESH:D000095027), sudden cardiac death (MESH:D016757), fatigue (MESH:D005221), myocardial injury (MESH:D009202), chest pain (MESH:D002637), Obesity (MESH:D009765), NSTEMI (MESH:D000072657), Arrhythmia (MESH:D001145), nausea (MESH:D009325), anxiety (MESH:D001007), ventricular dysfunction (MESH:D018754), Angina (MESH:D000787), Diabetes mellitus (MESH:D003920), cardiogenic shock (MESH:D012770), dyspnea (MESH:D004417), ACS (MESH:D054058), bodily pain (MESH:D010146), Syncope (MESH:D013575), platelet aggregation (MESH:D001791), inflammation (MESH:D007249), joint injury (MESH:D000092464), myocardial cell necrosis (MESH:D002292), AE (MESH:D000092202), cardiac overload (MESH:D006331), depression (MESH:D003866), infarction (MESH:D007238), Heart failure (MESH:D006333), coronary artery occlusion (MESH:D054059), orthostatic hypotension (MESH:D007024), myocardial ischemia (MESH:D017202), hypoglycemia (MESH:D007003), cardiovascular (MESH:D002318), MI (MESH:D009203), atherosclerotic (MESH:D050197), CE (MESH:D005597), cardiac death (MESH:D003643), Hypertension (MESH:D006973), thrombus (MESH:D013927)
- **Chemicals:** blood glucose (MESH:D001786), oxygen (MESH:D010100), sugar (MESH:D000073893), ROS (MESH:D017382), CE (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12968203/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12968203/full.md

## References

70 references — full list in the complete paper: https://tomesphere.com/paper/PMC12968203/full.md

---
Source: https://tomesphere.com/paper/PMC12968203